Cargando…

IL-37 Gene Modification Enhances the Protective Effects of Mesenchymal Stromal Cells on Intestinal Ischemia Reperfusion Injury

BACKGROUND: Ischemia reperfusion injury (IRI) is the major cause of intestinal damage in clinic. Although either mesenchymal stromal cells (MSCs) or interleukin 37 (IL-37) shows some beneficial roles to ameliorate IRI, their effects are limited. In this study, the preventative effects of IL-37 gene-...

Descripción completa

Detalles Bibliográficos
Autores principales: Kong, Dejun, Hu, Yonghao, Li, Xiang, Yu, Dingding, Li, Hongyue, Zhao, Yiming, Qin, Yafei, Jin, Wang, Zhang, Baoren, Wang, Bo, Wang, Hongda, Li, Guangming, Wang, Hao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7439787/
https://www.ncbi.nlm.nih.gov/pubmed/32849879
http://dx.doi.org/10.1155/2020/8883636
_version_ 1783573048616550400
author Kong, Dejun
Hu, Yonghao
Li, Xiang
Yu, Dingding
Li, Hongyue
Zhao, Yiming
Qin, Yafei
Jin, Wang
Zhang, Baoren
Wang, Bo
Wang, Hongda
Li, Guangming
Wang, Hao
author_facet Kong, Dejun
Hu, Yonghao
Li, Xiang
Yu, Dingding
Li, Hongyue
Zhao, Yiming
Qin, Yafei
Jin, Wang
Zhang, Baoren
Wang, Bo
Wang, Hongda
Li, Guangming
Wang, Hao
author_sort Kong, Dejun
collection PubMed
description BACKGROUND: Ischemia reperfusion injury (IRI) is the major cause of intestinal damage in clinic. Although either mesenchymal stromal cells (MSCs) or interleukin 37 (IL-37) shows some beneficial roles to ameliorate IRI, their effects are limited. In this study, the preventative effects of IL-37 gene-modified MSCs (IL-37-MSCs) on intestinal IRI are investigated. METHODS: Intestinal IRI model was established by occluding the superior mesenteric artery for 30 minutes and then reperfused for 72 hours in rats. Forty adult male Sprague-Dawley rats were randomly divided into the sham control, IL-37-MSC-treated, MSC-treated, recombinant IL-37- (rIL-37-) treated, and untreated groups. Intestinal damage was assessed by H&E staining. The levels of gut barrier function factors (diamine oxidase and D-Lactate) and inflammation cytokine IL-1β were assayed using ELISA. The synthesis of tissue damage-related NLRP3 inflammasome and downstream cascade reactions including cleaved caspase-1, IL-1β, and IL-18 was detected by western blot. The mRNA levels of proinflammatory mediators IL-6 and TNF-α, which are downstream of IL-1β and IL-18, were determined by qPCR. Data were analyzed by one-way analysis of variance (ANOVA) after the normality test and followed by post hoc analysis with the least significant difference (LSD) test. RESULTS: IL-37-MSCs were able to migrate to the damaged tissue and significantly inhibit intestinal IRI. As compared with MSCs or the rIL-37 monotherapy group, IL-37-MSC treatment both improved gut barrier function and decreased local and systemic inflammation cytokine IL-1β level in IRI rats. In addition, tissue damage-related NLRP3 and downstream targets (cleaved caspase-1, IL-1β, and IL-18) were significantly decreased in IRI rats treated with IL-37-MSCs. Furthermore, IL-1β- and IL-18-related proinflammatory mediator IL-6 and TNF-α mRNA expressions were all significantly decreased in IRI rats treated with IL-37-MSCs. CONCLUSION: The results suggest that IL-37 gene modification significantly enhances the protective effects of MSCs against intestinal IRI. In addition, NLRP3-related signaling pathways could be associated with IL-37-MSC-mediated protection.
format Online
Article
Text
id pubmed-7439787
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-74397872020-08-25 IL-37 Gene Modification Enhances the Protective Effects of Mesenchymal Stromal Cells on Intestinal Ischemia Reperfusion Injury Kong, Dejun Hu, Yonghao Li, Xiang Yu, Dingding Li, Hongyue Zhao, Yiming Qin, Yafei Jin, Wang Zhang, Baoren Wang, Bo Wang, Hongda Li, Guangming Wang, Hao Stem Cells Int Research Article BACKGROUND: Ischemia reperfusion injury (IRI) is the major cause of intestinal damage in clinic. Although either mesenchymal stromal cells (MSCs) or interleukin 37 (IL-37) shows some beneficial roles to ameliorate IRI, their effects are limited. In this study, the preventative effects of IL-37 gene-modified MSCs (IL-37-MSCs) on intestinal IRI are investigated. METHODS: Intestinal IRI model was established by occluding the superior mesenteric artery for 30 minutes and then reperfused for 72 hours in rats. Forty adult male Sprague-Dawley rats were randomly divided into the sham control, IL-37-MSC-treated, MSC-treated, recombinant IL-37- (rIL-37-) treated, and untreated groups. Intestinal damage was assessed by H&E staining. The levels of gut barrier function factors (diamine oxidase and D-Lactate) and inflammation cytokine IL-1β were assayed using ELISA. The synthesis of tissue damage-related NLRP3 inflammasome and downstream cascade reactions including cleaved caspase-1, IL-1β, and IL-18 was detected by western blot. The mRNA levels of proinflammatory mediators IL-6 and TNF-α, which are downstream of IL-1β and IL-18, were determined by qPCR. Data were analyzed by one-way analysis of variance (ANOVA) after the normality test and followed by post hoc analysis with the least significant difference (LSD) test. RESULTS: IL-37-MSCs were able to migrate to the damaged tissue and significantly inhibit intestinal IRI. As compared with MSCs or the rIL-37 monotherapy group, IL-37-MSC treatment both improved gut barrier function and decreased local and systemic inflammation cytokine IL-1β level in IRI rats. In addition, tissue damage-related NLRP3 and downstream targets (cleaved caspase-1, IL-1β, and IL-18) were significantly decreased in IRI rats treated with IL-37-MSCs. Furthermore, IL-1β- and IL-18-related proinflammatory mediator IL-6 and TNF-α mRNA expressions were all significantly decreased in IRI rats treated with IL-37-MSCs. CONCLUSION: The results suggest that IL-37 gene modification significantly enhances the protective effects of MSCs against intestinal IRI. In addition, NLRP3-related signaling pathways could be associated with IL-37-MSC-mediated protection. Hindawi 2020-08-07 /pmc/articles/PMC7439787/ /pubmed/32849879 http://dx.doi.org/10.1155/2020/8883636 Text en Copyright © 2020 Dejun Kong et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Kong, Dejun
Hu, Yonghao
Li, Xiang
Yu, Dingding
Li, Hongyue
Zhao, Yiming
Qin, Yafei
Jin, Wang
Zhang, Baoren
Wang, Bo
Wang, Hongda
Li, Guangming
Wang, Hao
IL-37 Gene Modification Enhances the Protective Effects of Mesenchymal Stromal Cells on Intestinal Ischemia Reperfusion Injury
title IL-37 Gene Modification Enhances the Protective Effects of Mesenchymal Stromal Cells on Intestinal Ischemia Reperfusion Injury
title_full IL-37 Gene Modification Enhances the Protective Effects of Mesenchymal Stromal Cells on Intestinal Ischemia Reperfusion Injury
title_fullStr IL-37 Gene Modification Enhances the Protective Effects of Mesenchymal Stromal Cells on Intestinal Ischemia Reperfusion Injury
title_full_unstemmed IL-37 Gene Modification Enhances the Protective Effects of Mesenchymal Stromal Cells on Intestinal Ischemia Reperfusion Injury
title_short IL-37 Gene Modification Enhances the Protective Effects of Mesenchymal Stromal Cells on Intestinal Ischemia Reperfusion Injury
title_sort il-37 gene modification enhances the protective effects of mesenchymal stromal cells on intestinal ischemia reperfusion injury
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7439787/
https://www.ncbi.nlm.nih.gov/pubmed/32849879
http://dx.doi.org/10.1155/2020/8883636
work_keys_str_mv AT kongdejun il37genemodificationenhancestheprotectiveeffectsofmesenchymalstromalcellsonintestinalischemiareperfusioninjury
AT huyonghao il37genemodificationenhancestheprotectiveeffectsofmesenchymalstromalcellsonintestinalischemiareperfusioninjury
AT lixiang il37genemodificationenhancestheprotectiveeffectsofmesenchymalstromalcellsonintestinalischemiareperfusioninjury
AT yudingding il37genemodificationenhancestheprotectiveeffectsofmesenchymalstromalcellsonintestinalischemiareperfusioninjury
AT lihongyue il37genemodificationenhancestheprotectiveeffectsofmesenchymalstromalcellsonintestinalischemiareperfusioninjury
AT zhaoyiming il37genemodificationenhancestheprotectiveeffectsofmesenchymalstromalcellsonintestinalischemiareperfusioninjury
AT qinyafei il37genemodificationenhancestheprotectiveeffectsofmesenchymalstromalcellsonintestinalischemiareperfusioninjury
AT jinwang il37genemodificationenhancestheprotectiveeffectsofmesenchymalstromalcellsonintestinalischemiareperfusioninjury
AT zhangbaoren il37genemodificationenhancestheprotectiveeffectsofmesenchymalstromalcellsonintestinalischemiareperfusioninjury
AT wangbo il37genemodificationenhancestheprotectiveeffectsofmesenchymalstromalcellsonintestinalischemiareperfusioninjury
AT wanghongda il37genemodificationenhancestheprotectiveeffectsofmesenchymalstromalcellsonintestinalischemiareperfusioninjury
AT liguangming il37genemodificationenhancestheprotectiveeffectsofmesenchymalstromalcellsonintestinalischemiareperfusioninjury
AT wanghao il37genemodificationenhancestheprotectiveeffectsofmesenchymalstromalcellsonintestinalischemiareperfusioninjury